Evidence digest
What the research on Tesamorelin actually shows
The indexed literature on Tesamorelin includes human clinical or observational records (4 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether Tesamorelin is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
Updated 25 Aug 2026 · 4 studies indexed · 4 human · compound record
- Studies indexed
- 4
- Human evidence
- 4
- Preclinical only
- 0
What is and is not established
What the literature supports
- Human clinical or observational records are indexed for Tesamorelin (4).
- Published research is indexed back to 2003, with roughly 120 PubMed records located.
- It is listed by one or more vendors tracked in this index.
What is NOT established
- This index does not evaluate whether Tesamorelin is safe or effective for any use.
- Material sold by the vendors indexed here is labeled for laboratory research use only and is not a regulator-approved medicine in that form.
- No dosing, protocol or human-use guidance is provided or implied anywhere in this index.
Studies indexed
2 human — controlled trial · 1 meta-analysis · 1 case report
| Study | Evidence type | Model | n | What it reported | Source |
|---|---|---|---|---|---|
| Efficacy and safety of tesamorelin in people with HIV on integrase inhibitorsAIDS (London, England) · 2024 | Human — controlled trial | Not recorded | — | Tesamorelin is the only FDA-approved therapy to treat abdominal fat accumulation in people with HIV (PWH). Phase III clinical trials were conducted prior to the introduction of integrase inhibitors (INSTIs), which are now a mainstay of HIV antiretroviral therapy. We leveraged a randomized double-blind trial of 61 PWH and metabolic dysfunction-associated steatotic liver disease to evaluate the efficacy and safety of tesamorelin 2 mg once daily vs. identical placebo amon… | PMID 38905488 |
| Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trialsObesity research & clinical practice · 2026 | Meta-analysis | Not recorded | — | HIV-associated lipodystrophy leads to visceral fat accumulation, metabolic complications, body image concerns, medication non-adherence, and increased cardiovascular risks. We thought to assess the effects of Tesamorelin, a synthetic growth hormone-releasing hormone analogue, that has been proposed as a targeted therapy. We systematically searched PubMed, Embase, Scopus, Web of Science, and CENTRAL through July 2025 for randomized controlled trials (RCTs) evaluating Tesamorel… | PMID 41545261 |
| Approach to the Patient With LipodystrophyThe Journal of clinical endocrinology and metabolism · 2022 | Case report | Not recorded | — | Lipodystrophy constitutes a spectrum of diseases characterized by a generalized or partial absence of adipose tissue. Underscoring the role of healthy fat in maintenance of metabolic homeostasis, fat deficiency in lipodystrophy typically leads to profound metabolic disturbances including insulin resistance, hypertriglyceridemia, and ectopic fat accumulation. While rare, recent genetic studies indicate that lipodystrophy is more prevalent than has been previously thought, sugg… | PMID 35137140 |
| Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal ObesityThe Journal of infectious diseases · 2025 | Human — controlled trial | Not recorded | — | In people with HIV who are virally suppressed with antiretroviral therapy, abdominal obesity (AO) is linked to neurocognitive impairment (NCI), potentially due to visceral adiposity, inflammation, and reduced insulin-like growth factor 1 (IGF-1). Tesamorelin, a growth hormone-releasing hormone, reduces AO and increases IGF-1, suggesting that it might mitigate NCI in people with HIV and viral suppression. This 6-month phase 2 randomized open-label clinical trial compared tesam… | PMID 39813152 |
Vendors listing Tesamorelin
The evidence above describes the published literature. What any individual vial contains is a separate question, answered by that vendor’s certificate records rather than by any study on this page.
| Vendor | Score · Coverage | Certificates | |
|---|---|---|---|
| Curo | 93.877% | 1 | profile → |
| Polaris Peptides | 93.877% | 3 | profile → |
| Next Gen Peptides | 93.897% | 6 | profile → |
| Ascend Science | 90.291% | 3 | profile → |
| PeptidePlugs | 89.790% | 4 | profile → |
| Protide Health | 83.994% | 0 | profile → |
| American Peptides | 83.6100% | 3 | profile → |
| Origin Labs | 81.885% | 1 | profile → |
| Northline Labs | 79.493% | 1 | profile → |
| NeuroLabs Research | 79.386% | 1 | profile → |
| Koi Peptides | 79.394% | 0 | profile → |
| ZC Labs | 79.384% | 4 | profile → |
| Good Science Bio | 79.275% | 0 | profile → |
| Ascension Peptides | 78.186% | 1 | profile → |
| Licensed Peptides | 7789% | 1 | profile → |
| Peptime | 75.359% | 1 | profile → |
| Modern Aminos | 74100% | 2 | profile → |
| Simple Peptide | 7489% | 2 | profile → |
| Vertex Labs | 70.170% | 1 | profile → |
| Improved Peptides | 7089% | 1 | profile → |
| Disguised Alpha | 69.150% | 0 | profile → |
| Eternal Peptides | 68.265% | 0 | profile → |
| BioLongevity Labs | 67.274% | 0 | profile → |
| Mile High Compounds | 65.494% | 0 | profile → |
| Extreme Peptides | 64.282% | 1 | profile → |
| Sports Technology Labs | 56.174% | 0 | profile → |
How to read this page
This digest describes what published research exists and what it does not establish. It is not a recommendation, contains no dosing information or protocols, and makes no claim that any compound is safe or effective for any purpose. Material listed by indexed vendors is labeled for laboratory research use only.